 "Divi's Laboratories plant")
Divi’s Laboratories has moved higher by 6% to Rs 915 on BSE in intra-day trade after the company announced that all the previous observations by US drug regulator regarding Unit-2 of its Visakhapatnam facility have been confirmed as completed and resolved.
The stock hit nine-month high and was trading at its highest level since December 23, 2016 on BSE. It outperformed the market by surging 47% in past one month, as compared to 4% rise in the S&P BSE Sensex.
“Unit-2 has been inspected by the U.S. Food and Drug Administration (US-FDA) from September 11 to September 19,
The stock hit nine-month high and was trading at its highest level since December 23, 2016 on BSE. It outperformed the market by surging 47% in past one month, as compared to 4% rise in the S&P BSE Sensex.
“Unit-2 has been inspected by the U.S. Food and Drug Administration (US-FDA) from September 11 to September 19,
